Evidence map›Paper›PMID 41733867›Full record

ArticleJournal of neuro-oncology2026

Repeat resection for recurrent glioblastoma - does timing matter?

Obada T Alhalabi, Kirill Mironov, Khurshed Nabiev, Johanna Krämer, Nour Gareib, Henri Olldashi, Stefan Joser, Marianne Schell, Sandro M Krieg, Andreas W Unterberg and 1 more

Abstract read
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Obada T AlhalabiDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. obada.alhalabi@med.uni-heidelberg.de.
Kirill MironovDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Khurshed NabievDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Johanna KrämerDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Nour GareibDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Henri OlldashiDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Stefan JoserDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Marianne SchellDepartment of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
Sandro M KriegDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Andreas W UnterbergDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Christine JungkDepartment of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe optimal timing of repeat surgical resection in patients with recurrent IDH-wildtype glioblastoma (rGB) remains unclear. We aimed to characterize temporal patterns between radiological suspicion of recurrence and repeat resection and to evaluate the impact of early versus delayed surgery on the extent of resection (EOR), functional outcomes, adjuvant therapy, and survival

methodsWe retrospectively analyzed a consecutive cohort of 150 patients who underwent resection for histopathologically confirmed rGB between 2015 and 2023 at a single tertiary care center. Assessment of contrast-enhancing preoperative and residual tumor volumes (RTV on early postoperative MRI) was performed using semi-automated segmentation. Based on the mean or median time between suspicion of recurrence and repeat resection, patients were stratified into early and late surgery groups. RANO Resect criteria and a 0.175-ml RTV threshold were used to classify EOR. Functional outcomes, postoperative treatment, as well as progression-free survival (PFS) after repeat resection, and overall survival (OS) after suspicion of recurrence were compared between groups.

resultsMean and median time from suspicion of recurrence to repeat resection were 54 and 24 days, respectively, with 75% of patients undergoing reoperation within 6 weeks. Applying the mean cut-off, early (n=120) and late (n=30) surgery groups showed comparable baseline demographics, performance status, tumor eloquence, and preoperative neurological deficits. Preoperative tumor volumes were significantly smaller in the early surgery group (12.7 vs. 25.9 ml, p=0.002). Late surgery was associated with a trend toward higher RTV and lower rates of gross total resection, though without statistical significance. Rates of transient and permanent postoperative neurological deficits were low (15% and 2%) and did not differ between groups. Adjuvant treatment patterns differed, with early surgery patients more frequently receiving CCNU-based chemotherapy, while late surgery patients more often received no further treatment. Median OS after suspicion of recurrence (12.4 vs 14.3 months) and PFS after repeat resection (4 months in both groups) were not significantly different between early and late surgery groups. A re-analysis using the median of 24 days as cut-off revealed similar results with regards to survival and functional outcomes.

conclusionMost patients with repeat resections for rGB underwent surgery shortly after radiological suspicion of recurrence. While delayed surgery was associated with larger tumor volumes and a trend toward less favorable EOR and adjuvant treatment, timing of surgery alone was not associated with functional outcomes or survival. These findings support individualized decision-making for repeat resection based on clinical and radiological factors rather than timing alone.

Indexed as

Brain NeoplasmsGlioblastomaNeoplasm Recurrence, LocalNeurosurgical ProceduresReoperationAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesSurvival RateTime FactorsPseudo-progressionRecurrent glioblastomaRepeat resectionTiming of surgeryVolumetric analysis

Identifiers

PMID41733867
PMCPMC12932274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.